Stock Market Reviews

CRNX (Crinetics Pharmaceuticals, Inc.) News

Get the latest news, insights, and market updates on CRNX (Crinetics Pharmaceuticals, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Amid Economic Date Releases
  The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1% and the actively tr
  Jan 7, 2026 - $CRNX
• Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
  SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics”), a pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today the pricing of an underwritten public offering of 7,620,000 shares of its common stock at a price to the public of $45.95 per share. All of the shares to be sold in the offering are to be sold by Crinetics. The gross
  Jan 7, 2026 - $CRNX
• Crinetics Pharmaceuticals Reports Palsonify Preliminary Revenue, Atumelnant Trial Progress
  Crinetics Pharmaceuticals (CRNX) said Monday it expects over $5 million in preliminary Q4 2025 US re
  Jan 5, 2026 - $CRNX
• Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
  SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics”), a pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today that it intends to offer and sell, subject to market and other conditions, $350.0 million of shares of its common stock in a proposed underwritten public offering. In addition, Crinetics intends to grant the underwrit
  Jan 5, 2026 - $CRNX
• Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia
  Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Atumelnant (80 mg) Achieved a 67% Mean Reduction in Androstenedione Levels While Simultaneously Enabling 88% of Participants Completing 12 Weeks of Treatment to Successfully Reduce Glucocorticoid Dose to Physiologic Replacement Levels Atumelnant's Favorable Benefit/Risk Profile Was Maintained in Cohort 4 and Ope
  Jan 5, 2026 - $CRNX
• Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
  SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET to provide an update on PALSONIFY™ (paltusotine) commercialization and disclose topline results from the fourth cohort of the Phase 2 trial of atumelnant in congenital adrenal hyperplasia. Conference Call and Webcast DetailsManagement will hold a live conference call and webcast on Monday,
  Jan 4, 2026 - $CRNX
• Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
  SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will present at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Tuesday, January 13, 2026 at 9:45 a.m. Pacific Time. To access the live audio-only webcast, click here. The archived webcast will also be accessible on the Events & Presentations page in the Investors secti
  Dec 18, 2025 - $CRNX
• Does Crinetics Pharmaceuticals Still Offer Value After Its Recent Share Price Rebound?
  If you are wondering whether Crinetics Pharmaceuticals at around $50 a share is a hidden gem or already priced for perfection, you are not alone. That is exactly what we are going to unpack. The stock has climbed 8.2% over the last week and 17.9% over the past month, but that still sits against a -2.1% year to date return and a -5.9% slide over the last year, even after a 199.6% gain over 3 years and 284.2% over 5 years. Those swings have been driven by shifting expectations around the...
  Dec 13, 2025 - $CRNX
• Crinetics Pharmaceuticals Says First Patient Dosed in Phase 3 Trial of Atumelnant for Classic CAH
  Crinetics Pharmaceuticals (CRNX) said late Thursday it has dosed the first patient in a Phase 3 clin
  Dec 11, 2025 - $CRNX
• Crinetics Pharmaceuticals (CRNX) Poised for Transformational Growth in 2026: Piper Sandler
  Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, Piper Sandler reiterated that Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the stocks to own as the company is poised for transformational growth in 2026. According to the research firm, the company is staring […]
  Dec 11, 2025 - $CRNX